Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A few doubts creeping in?I was a bit naive as I thought Kauna was a done deal
Dallo. The deal might not go through if :
• the lawsuit prevents it from doing so or
• the Karuna shareholders vote against it.
It’s clear there are a lot of disgruntled shareholders who feel the board are materially undervaluing KarXT. If the deal does not go through, I’m pretty sure the Karuna share price and most likely the PureTech share price will react negatively to the news. I will view this as a wonderful buying opportunity as it’s quite clear Karuna is worth at least $14B
Golf nut
In the unlikely event that Karuna shareholders vote against the BMS takeover , it only means that the price of the bid is too low and then would immediately open up a bidding war as other major Pharmas make their move.
Either way still great for Puretech imho.
Thanks golf, I agree. Also the listed market cap is $12bn currently, capturing the uncertainty there too.
Having said that, in either scenario it’s only a matter of time for prtc
Big date for PRTC shareholders on 12th March as that's the day the Karuna shareholders vote on whether to go ahead with the BMS merger. Its well documented that many of the shaeholders believe $14B is selling the company short so the vote is definietly not a formality. In addition, the lawsuit by shareholder Jenkins aginast the company could also throw a spanner in the works resulting in the merger failing. Fingers crossed the deal goes through or I think we will see PRTC sell off a bit. PRTC share price suggests market is certainly cautious and in wait and see mode
Ews & Insights
STOCKS
Zacks-Logo
Down -8.13% in 4 Weeks, Here's Why PureTech Health PLC Sponsored ADR (PRTC) Looks Ripe for a Turnaround
February 15, 2024 — 09:35 am EST
Written by Zacks Equity Research for Zacks ->
PureTech Health PLC Sponsored ADR (PRTC) has been beaten down lately with too much selling pressure. While the stock has lost 8.1% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.
Here is How to Spot Oversold Stocks
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls
I get the impression the septics also expect this to boom 💥 big time
Not really useful linking or posting … outdated without links
I think you’ll find that’s old news. I get all PRTC updates live to my email.
Sorry wrong link lol 😂
It was there this morning ??
It was posted on the 29 of feb
****nal
i cannot find relevant puretech mention in tipranks.
anything of interest
I just topped up. Maxed out also now
....the most exciting and well supported investment currently and I suspect its SP will rocket over a rather short space of time. I have filled up here. Check it out and so will you!
Ars,
Hopefully Puretech will RNS this information later today when US markets open
Cheers
have you got a link or article to it ****nal?
PureTech Health’s fully human anti-galectin-9 IgG4 monoclonal antibody was granted FDA orphan status as a treatment of Acute Myeloid Leukemia, according to a post to the agency’s website.
Published first on – the ultimate source for real-time, market-moving breaking financial news.
PureTech Health treatment of Acute Myeloid Leukemia granted FDA orphan status
Lesley, The only way Puretech would be at £1 in a year is if they were facing some kind of serious litigation against them. They have £1 cash per share pre Karuna. By May / June, we will have £2 per share and then by September with further milestone payments closer to £2.50 per share in the bank.
A couple of false dawns recently but I dare not trade this. Always a chance of waking up to a £4+ cash offer which would be cheap.
Oldernowiser
Good to see you joining the Puretech chat..we are both involved in Immupharma.
However Puretech is a cash rich exciting Pharma company with major catalysts in the coming months.
Immupharma is interesting with risk / reward of a different dimension to Puretech.
Best of luck
A crystal ball wouldn't help work out the SP for Puretech.It could be doubled or halved by the end of the year
...now I know the potential!
Thank you.